Clozapine to prevent violent behavior in people with schizophrenia
2/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
This trial will compare clozapine with usual treatment to see if it lowers the chance of violent acts in people with schizophrenia who are at high risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11134600 on NIH RePORTER |
What this research studies
If you join, you would be randomly assigned to take clozapine or to continue usual antipsychotic care for 24 weeks. The trial is open-label (you and your doctors will know the medication) and a blinded rater will track outcomes at regular visits. About 280 adults at seven U.S. sites will be enrolled, and the main outcome is time until a violent act occurs. The study is coordinated by the New York State Psychiatric Institute and includes regular safety monitoring required for clozapine.
Who could benefit from this research
Good fit: Adults with schizophrenia who are considered at high risk for violent behavior and who can comply with clozapine’s medical monitoring would be ideal candidates.
Not a fit: People without schizophrenia, those at low risk for violence, or those who cannot tolerate clozapine or meet its monitoring requirements may not receive benefit from this trial.
Why it matters
Potential benefit: If successful, this could show clozapine reduces violent behavior and improve safety and quality of life for people with schizophrenia.
How similar studies have performed: Smaller or observational studies suggest clozapine can reduce aggression, but no large randomized community trial has definitively proven this effect.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Goff, Donald C. — New York University School of Medicine
- Study coordinator: Goff, Donald C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.